Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 77
Filter
2.
Pediatr Int ; 43(4): 354-60, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11472578

ABSTRACT

BACKGROUND: The CD44, a cell surface proteoglycan, participates in a variety of function including tumor dissemination and metastasis. However, there are no available data on the prognostic significance of CD44 expression of tumor tissue correlated with serum sCD44 level in childhood leukemias and lymphomas. METHODS: Serum levels and leukemic cell tumor tissue expression of CD44 were detected in 54 children with acute leukemia and malignant lymphoma. Serum samples were obtained from all patients before treatment and during remission. Twelve age-matched healthy children were included as a control group. RESULTS: The serum CD44 levels were significantly higher in patients with Hodgkin's disease (HD), non-Hodgkin's lymphoma (NHL), Burkitt's lymphoma (BL) and acute lymphoblastic leukemia (ALL) than those in the control group. The median values were 1627.0, 1336.0, 1318.5, 1730.4, 902.7 ng/mL, respectively, and P<0.001, P<0.01, P<0.01, P<0.05 in comparisons, respectively. However, there was no significant difference between acute myeloid leukemia (AML) and the control group (median values: 900.3 and 902.7 ng/mL, respectively, P>0.05). Serum sCD44 levels significantly declined in HD, NHL and ALL patients who were in complete remission (median values: 684.0, 573.8 and 1101.1 ng/mL, respectively, P<0.05 in each comparison). Patients with HD had higher levels of serum sCD44 and correlated well with higher erythrocyte sedimentation rate (ESR), B-symptoms and advanced-stage disease (P<0.05, P<0.05 and P<0.01, respectively). Expression of CD44 was significantly high in patients with HD and NHL who were in advanced stages of disease. High serum CD44 level was also associated with high tumor tissue expression of CD44 in patients with HD and BL. In addition, patients with higher levels of serum sCD44, had a poorer outcome and survival than those with lower sCD44 levels in HD and NHL groups. CONCLUSIONS: A high serum sCD44 level and/or tumor tissue expression at diagnosis is associated with poor prognostic criteria and/or unfavorable outcome in childhood leukemias and lymphomas.


Subject(s)
Burkitt Lymphoma/metabolism , Hodgkin Disease/metabolism , Hyaluronan Receptors/metabolism , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Adolescent , Burkitt Lymphoma/blood , Burkitt Lymphoma/mortality , Child , Child, Preschool , Female , Hodgkin Disease/blood , Hodgkin Disease/mortality , Humans , Hyaluronan Receptors/blood , Infant , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Prognosis
3.
Pediatr Hematol Oncol ; 17(2): 133-9, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10734655

ABSTRACT

In this study peripheral blood natural killer (NK) cell activity was evaluated in 17 pediatric cases with Hodgkin disease (HD) (9 untreated, 8 in remission) and 20 age-matched healthy children. Peripheral blood CD16 and CD56 molecule expressions were also examined. No difference related to NK cell numbers and cytotoxic activity was detected at either stage of the disease. In cases in which long-term remission has been achieved (> or = 5 years) NK cell activity was slightly but not significantly increased in parallel with remission duration. Finally, no relation between NK cell activity and the etiology, prognosis, and severity of the disease has been established in children with HD.


Subject(s)
Cytotoxicity, Immunologic , Hodgkin Disease/blood , Hodgkin Disease/immunology , Killer Cells, Natural , Adolescent , Adult , CD56 Antigen/blood , Cell Count , Child , Child, Preschool , Female , Humans , Killer Cells, Natural/metabolism , Killer Cells, Natural/pathology , Male , Receptors, IgG/blood , Turkey/epidemiology
4.
Pediatr Hematol Oncol ; 16(4): 299-309, 1999.
Article in English | MEDLINE | ID: mdl-10407866

ABSTRACT

The complications of right atrial catheters (RACs) in pediatric oncology patients are unknown for centers in developing countries. This study examined the complications of RACs at Ankara University Medical School, Turkey. A total of 90 RACs were placed in 61 children for long-term chemotherapy with a total experience of 15,536 catheter days. The rate of catheter-related sepsis was 4.9 episodes per 1000 catheter days. Coagulase-negative staphylococci and Candida species were the most common organisms, accounting for 25.0 and 13.1% of all organisms, respectively. The most common reasons for the removal of the RACs were infection (42.4%) and dislodgement (32.2%). The rates of complications were significantly higher in this study than in western studies. This increase could be explained by the differences in catheter care practices in the Turkish center. In conclusion, the use of RACs in a developing country necessitates an appraisal of the benefits and risks for each patient and improvement of catheter care procedures.


Subject(s)
Catheterization, Central Venous/adverse effects , Catheters, Indwelling/adverse effects , Neoplasms/therapy , Adolescent , Child , Child, Preschool , Developing Countries , Humans , Infant , Infections/etiology
5.
Pediatr Hematol Oncol ; 16(2): 149-58, 1999.
Article in English | MEDLINE | ID: mdl-10100275

ABSTRACT

Serum levels and leukemic cell-tumor tissue expression of intracellular adhesion molecule-1 (ICAM-1/CD 54) were detected in 54 children with acute leukemia and malignant lymphoma. Serum samples were obtained from all patients before treatment and after cessation of the therapy from malignant lymphoma cases and during remission from leukemic patients. Twelve age-matched healthy children were included as a control group. The serum ICAM-1 levels were significantly higher in patients with acute lymphoblastic leukemia (ALL) or Hodgkin's disease (HD) than those in the control group (median values: 350.9, 286.4, and 138.4 ng/mL, respectively; P < .01 in each comparison). However, there were no significant differences concerning serum ICAM-1 levels between the control group and each of the acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), and Burkitt's lymphoma (BL) case groups (median values: 235.7, 222.7, 195.9, and 138.4 ng/mL, respectively; P > .05 in each comparison). Moreover, serum soluble ICAM-1 levels significantly declined in ALL or HD patients who were in complete remission (median values: 185.0 and 145.4 ng/mL, respectively; P < .05 in each comparison). In HD patients high levels of serum ICAM-1 could be correlated with high ESR (P < .01), whereas no statistically significant difference could be found when serum ICAM-1 titers were compared with stages, B symptoms, and histological subgroups, probably because of the inadequate number of patients in each group. Expression of ICAM-1 was mainly attributed to lymphocytes, vessels, and weakly to Hodgkin's cells, and this was significantly high in patients who were in advanced stages of disease. High serum sICAM-1 level was also associated with poor outcome and survival. Determination of serum level and/or tumor tissue expression of ICAM-1 in HD and ALL might represent an additional, but probably not independent, disease-associated marker to be used in the evaluation and/or monitoring of treatment response in patients with HD and ALL.


Subject(s)
Intercellular Adhesion Molecule-1/blood , Leukemia, Myeloid/immunology , Lymphoma/immunology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology , Acute Disease , Adolescent , Child , Child, Preschool , Female , Humans , Infant , Leukemia, Myeloid/mortality , Leukemia, Myeloid/pathology , Lymphoma/mortality , Lymphoma/pathology , Male , Neoplasm Staging , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Prognosis , Remission Induction , Solubility , Survival Rate
7.
Leukemia ; 12(11): 1796-805, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9823956

ABSTRACT

Burkitt's lymphoma (BL) in Turkish children is commonly associated with Epstein-Barr virus (EBV) infection. The C-terminus of the latent membrane protein 1 (LMP-1) of EBV is essential for transformation and the 30-bp deletion detected in this region has been implicated to be associated with a more aggressive malignant phenotype. To understand the molecular mechanisms underlying EBV pathogenesis in BL of Turkish children, we analyzed 30-bp deletion and 33-bp variable repeat regions of the LMP-1 gene from paraffin-embedded tumor tissues of 30 BL patients (mean age 5.9 years). Primer pairs spanning the 30-bp deletion and 33-bp repeat regions were designed for amplification by polymerase chain reaction (PCR). The PCR-amplified products were analyzed by gel electrophoresis, Southern blot hybridization, and DNA sequencing. Twenty-eight (93%) of 30 BL biopsy samples were EBV positive as determined by PCR. Variable copy numbers (ranging from 4.5 to 7) of the 33-bp repeat of LMP-1 gene were detected in these EBV-containing tumor samples. To determine the frequency of the 30-bp deletion of the LMP-1 gene, we sequenced the amplimers encompassing this region. Analyses of DNA sequence of 28 Turkish BLs have disclosed four patterns: the first (32% (9/28)) is identical to B95-8 with no deletion, the second (11% (3/28)) is identical to Asian NPC CAO strain with 30-bp deletion, the third (46% (13/28)) is prevalent in Turkish BLs with a longer deletion (69 bp), and the fourth (11% (3/28)) consists of a mixture of 30-bp and 69-bp deletion. The occurrence of high frequency of the 69-bp deletion appears to have no correlation with the disease site. Mutations found in the CAO strain were also detected in the Turkish BL clustering at the amino acids 322, 334, 338 and 342; whereas mutations specific for Turkish BL were clustered at amino acids 326, 352 and 361. To assess the EBV genotype with the changes in C-terminus of LMP-1 gene, we performed genotyping by PCR to differentiate type A and B strain. All 28 patients were infected by type A EBV. Such a high frequency of the larger size (69 bp) deletion has never been reported. Ascertaining the role of this deletion in BL pathogenesis will require further study.


Subject(s)
Burkitt Lymphoma/genetics , Herpesvirus 4, Human/genetics , Oncogene Proteins, Viral/genetics , Viral Matrix Proteins/genetics , Amino Acid Sequence , Base Sequence , Burkitt Lymphoma/ethnology , Child , DNA, Viral , Genotype , Humans , Molecular Sequence Data , Polymerase Chain Reaction , Sequence Deletion , Turkey
8.
Biol Trace Elem Res ; 54(2): 163-72, 1996 Aug.
Article in English | MEDLINE | ID: mdl-8886316

ABSTRACT

Selenium concentrations, in blood plasma, red blood cells, hair of 61 healthy children, ages 0-14 yr, were determined using hydride generation atomic absorption spectrometry. Starting from late lactation period, selenium concentrations in all these matrices were found to be increasing with age. A good correlation was found between erythrocyte and plasma, hair and plasma, and hair and erythrocyte selenium concentrations. Although plasma, erythrocyte, and hair selenium concentrations of girls seemed to be higher than that of boys (only in erythrocytes), selenium concentrations of girls were found to be significantly (p < 0.002) higher than that of boys, 71 +/- 9 ng/mL, vs 65 +/- 10 ng/mL, respectively. Selenium status of Turkish children is found to be lower than that found in the literature; marginal selenium deficiency could be important in the development of some selenium deficiency related diseases. There is a need for extension of this study to healthy children from different regions in Turkey and to different disease states.


Subject(s)
Erythrocytes/metabolism , Hair/metabolism , Selenium/blood , Adolescent , Aging/blood , Aging/metabolism , Aging/urine , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Regression Analysis , Selenium/metabolism , Selenium/urine , Spectrophotometry, Atomic , Turkey
9.
J Chemother ; 7(5): 463-6, 1995 Oct.
Article in English | MEDLINE | ID: mdl-8596134

ABSTRACT

We treated 137 Turkish children with biopsy-proven Hodgkin's disease, followed up between the years 1964 and 1989. Most patients were treated and were in advanced stage with histological subtype of mixed cellularity (67.5%). Radiotherapy (Mantle form) and/or MOPP, ABVD and OPPA combination chemotherapy regimens were used in 75.84% of patients. The follow-up period in these patients ranged from 5 to 24 years. The late effects in 28 patients who were evaluated for the late sequelae of chemoradiotherapy are presented. Seven out of 28 patients showed retarded sexual maturation. Testicular and ovarian functions were assessed in 11 patients, all of whom showed elevated serum FSH levels and 2 azoospermia. Analysis of thyroid functions was carried out in patients receiving radiotherapy to the neck. The thyroid gland was palpable in 6 patients. Further analysis showed diffuse hyperplasia in 5 and nodular in 1 patient. The nodule was excised and reported as "nodular colloidal goiter". Two patients had elevated TSH levels. "Swan-like neck" was observed in 3 patients who had received 40 to 42 Gy radiotherapy to the neck. Cirrhosis due to chronic hepatitis B infection was diagnosed in 2 patients as an unusual late complication. The secondary malignancy occurred in only 1 case in the form of "fibrosarcoma". The second neoplasm was probably radiation-induced as it occurred in the field of prior radiotherapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Endocrine Glands/drug effects , Endocrine Glands/radiation effects , Hodgkin Disease/therapy , Adolescent , Adult , Child , Combined Modality Therapy , Female , Follow-Up Studies , Hodgkin Disease/drug therapy , Hodgkin Disease/radiotherapy , Humans , Male , Puberty/drug effects , Puberty/radiation effects , Radiotherapy/adverse effects , Treatment Outcome
10.
J Chemother ; 7(5): 467-9, 1995 Oct.
Article in English | MEDLINE | ID: mdl-8596135

ABSTRACT

Neutropenic pediatric patients with solid tumors and malignant lymphomas were treated with recombinant granulocyte-macrophage colony stimulating factor (rh-GM-CSF). Eleven patients, including seven lympho-reticular malignancies, two Ewing's sarcoma and one patient in each group with the diagnosis of nasopharyngeal rhabdomyosarcoma, malignant mesenchymal tumor, entered the study. Six were females and five were males, the mean age was 10.4 yr, the range was 4 to 21 years. rh-GM-CSF was given at the dose of 5 micrograms/kg s.c. daily, starting either on the day following the last day of cytotoxic chemotherapy or when ANC < 1000/ml was determined. All patients received rh-GM-CSF for a total of seven days. Hematopoietic recovery occurred in all children except one. The response to rh-GM-CSF was achieved in a mean time of 7.4 days. Tolerance to rh-GM-CSF treatment was good. Adverse events were documented as fever, nausea, vomiting, fatigue, chills and itching. Sagittal sinus thrombosis developed in one patient 5 days following the completion of chemotherapy and rh-GM-CSF cycle. In conclusion, rh-GM-CSF can be applied during the intensive chemotherapy schedules of pediatric cancer patients.


Subject(s)
Antineoplastic Agents/adverse effects , Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use , Neoplasms/drug therapy , Neutropenia/drug therapy , Adolescent , Adult , Child , Child, Preschool , Female , Granulocyte-Macrophage Colony-Stimulating Factor/adverse effects , Humans , Male , Neoplasms/complications , Neutropenia/chemically induced , Recombinant Proteins/adverse effects , Recombinant Proteins/therapeutic use , Treatment Outcome
12.
Leuk Lymphoma ; 14(3-4): 323-30, 1994 Jul.
Article in English | MEDLINE | ID: mdl-7950922

ABSTRACT

Eighty-one Turkish children with Burkitt's lymphoma (BL) were observed during a period of 24 years (1968-1992). The diagnosis was established histologically according to WHO criteria. BL represented 48.5% of NHL in this series. The median age of patients was 5 years with a sex (M/F) ratio of 2.3/1. The most common primary site of tumor involvement at initial presentation was the abdomen (70.4%), which was followed by facial tumors, in particular the jaw and orbit (45.7%). The majority of the patients (84.0%) were in advanced stages (C and D) at initial diagnosis. Facial tumors observed in Turkish children with BL were more similar to African Burkitt's lymphoma than American or European cases. High titers of antibodies against VCA and EA of EBV were also observed in 32 recent cases of BL. Preliminary molecular and immunologic studies revealed EBV-DNA (type I) and T cell deficiency. The clinical presentation, median age, and association with EBV revealed that BL appears to be inbetween African and non-African types in Turkish children. This will be further elucidated in the future by direct examination of tumor cells for EBV and investigation of the molecular characteristics in these cases.


Subject(s)
Burkitt Lymphoma/epidemiology , Burkitt Lymphoma/virology , Herpesvirus 4, Human , Adolescent , Adult , Antibodies, Viral/analysis , Burkitt Lymphoma/immunology , CD4-CD8 Ratio , Child , Child, Preschool , Female , Herpesvirus 4, Human/immunology , Humans , Infant , Male , Turkey/epidemiology
13.
Cancer Genet Cytogenet ; 69(1): 38-40, 1993 Aug.
Article in English | MEDLINE | ID: mdl-8374898

ABSTRACT

A 6-year-old Turkish boy with bilateral orbito-ocular granulocytic sarcoma and AML is described. Cytogenetic studies on peripheral blood disclosed an abnormal hyperdiploid population with a double Ph chromosome. Despite intensive chemotherapy, he achieved only partial remission. Repeated cytogenetic studies on bone marrow during relapse revealed the persistence of double Ph chromosome. The aggressive course and the short survival time of this patient, despite adequate chemo-radiotherapy, may be explained by the presence of the double Ph chromosome.


Subject(s)
Eye Neoplasms/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Leukemia, Myeloid, Acute/genetics , Neoplasms, Multiple Primary/genetics , Orbital Neoplasms/genetics , Philadelphia Chromosome , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Child , Combined Modality Therapy , Cytarabine/administration & dosage , Dexamethasone/administration & dosage , Doxorubicin/administration & dosage , Etoposide/administration & dosage , Eye Neoplasms/drug therapy , Eye Neoplasms/radiotherapy , Humans , Karyotyping , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/radiotherapy , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/radiotherapy , Male , Methotrexate/administration & dosage , Multigene Family , Neoplasms, Multiple Primary/drug therapy , Neoplasms, Multiple Primary/radiotherapy , Orbital Neoplasms/drug therapy , Orbital Neoplasms/radiotherapy , Thioguanine/administration & dosage
14.
Med Oncol Tumor Pharmacother ; 10(3): 113-5, 1993.
Article in English | MEDLINE | ID: mdl-8264255

ABSTRACT

The aetiology of GS remains obscure and a little is known about the immune competence of these patients. Interestingly, all children with OOGS were from low 'socio-economic status' and showed diminished delayed hypersensitivity reactions and reduced T cell counts (E-R) in our previous observation. We present herewith a preliminary data on evaluation of T cell sub-populations determined by monoclonal antibodies (CD3, CD4, CD8 and CD16 cells) in 10 patients with OOGS and AML prior to treatment. Quantitative immunoglobulin determinations of IgA, IgM, IgG were also made. The percentage of Pan T (CD3), CD4, CD8 cells were significantly lower than those in the controls (p < 0.01). The immunoglobulin levels were slightly elevated suggesting normal B cell functions. In conclusion, these preliminary findings suggest that cellular immune deficiency may be an underlying cause.


Subject(s)
Eye Neoplasms/immunology , Leukemia, Myeloid, Acute/immunology , Leukemia, Myeloid/immunology , Orbital Neoplasms/immunology , T-Lymphocyte Subsets , CD3 Complex/analysis , CD4 Antigens/analysis , CD8 Antigens/analysis , Child , Child, Preschool , Female , Humans , Immunoglobulins/analysis , Immunophenotyping , Male , Receptors, IgG/analysis , T-Lymphocyte Subsets/immunology
15.
Med Pediatr Oncol ; 21(1): 36-42, 1993.
Article in English | MEDLINE | ID: mdl-8381202

ABSTRACT

Seventy-two Turkish children with Burkitt's lymphoma (BL) observed during a period of 22 years (1968-1990) have been analysed retrospectively. The diagnosis was established histologically according to WHO criteria. BL represented 50% of NHL in this series. The patients were staged according to Ziegler's system. The median age of patients was 5.5 years with a sex (M/F) ratio of 2.1/1. The most common primary site of tumor involvement was the abdomen (69.4%), which was followed by facial tumors, in particular the jaw and orbit (49.9%). There were 21 cases with jaw (29.1%) and 15 cases with orbital involvement (20.8%) at initial presentation. The majority of the patients (84.4%) were in advanced stages (C and D) at initial diagnosis. Facial tumors observed in Turkish children with BL were more similar to African Burkitt's lymphoma than American or European cases. High titers of antibodies against VCA and EA of EBV were also seen in our recent cases of BL. Two main treatment regimens, namely, single agent chemotherapy with cyclophosphamide (CYX) (1968-1974) and three drug (COM) combination chemotherapy, were used consecutively (1974-1988). COM has been shown to produce better results than single agent therapy. The clinical presentation, mean age, and high antibodies (IgG) to EBV and preliminary molecular studies revealed that BL appears to be in between African and non-African types in Turkish children. This will be further elucidated by direct examination of tumor cells for EBV and investigation of the molecular characteristics of Turkish tumors. Such studies are presently under way.


Subject(s)
Burkitt Lymphoma/classification , Burkitt Lymphoma/microbiology , Herpesvirus 4, Human/isolation & purification , Adolescent , Burkitt Lymphoma/immunology , Burkitt Lymphoma/metabolism , Child , Child, Preschool , DNA, Viral/analysis , Female , Humans , Male , Retrospective Studies , Turkey , Zinc/metabolism
16.
Biol Trace Elem Res ; 30(1): 81-5, 1991 Jul.
Article in English | MEDLINE | ID: mdl-1718371

ABSTRACT

Hair zinc concentration was measured in samples taken from 57 mothers who delivered infants with neural tube defects (NTD) (mainly anencephaly). Control groups consisted of 30 healthy mothers with normal offspring and 37 nonpregnant women from middle-income backgrounds. Zinc concentration was also measured in the hair of eight infants with NTD (four being anencephalic). The mean maternal hair zinc concentration in the NTD group (128.2 +/- 38.9 micrograms/g) was lower than that of the control women (p less than 0.001), whereas the mean hair zinc level of malformed babies (250.4 +/- 85.2 micrograms/g) was significantly higher than that of normal infants (193.4 +/- 39.2 micrograms/g) (p less than 0.05). Maternal nutritional zinc deficiency was thought to be one of the factors responsible for NTD in Turkey.


Subject(s)
Hair/chemistry , Neural Tube Defects/metabolism , Zinc/blood , Adolescent , Adult , Anencephaly/metabolism , Diet , Female , Humans , Infant, Newborn , Turkey
18.
Gynecol Obstet Invest ; 32(2): 123-5, 1991.
Article in English | MEDLINE | ID: mdl-1748322

ABSTRACT

The authors report a case of nutritional zinc deficiency in a young (18-year-old) Turkish woman, who previously delivered 2 anencephalic stillborn infants. The patient was supplemented with 22.5 mg oral zinc sulfate (100 mg ZnSO4.7H2O) for 5 months after her second delivery prior to her third pregnancy. Her blood (plasma and red blood cell) and hair zinc levels returned to normal following zinc supplementation. Good response to Zn supplementation was another criterion of Zn deficiency in this particular case. After an uneventful gestational period, she delivered an apparently normal full-term male child who has grown normally during the first 12 months.


Subject(s)
Anencephaly/prevention & control , Pregnancy Complications/drug therapy , Sulfates/therapeutic use , Zinc/deficiency , Zinc/therapeutic use , Adolescent , Deficiency Diseases/drug therapy , Female , Humans , Pregnancy , Zinc Sulfate
SELECTION OF CITATIONS
SEARCH DETAIL
...